C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection
Status:
Completed
Trial end date:
2018-10-30
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm trial in which patient who have ongoing antibody mediated
rejection of a kidney transplant deemed refractory to maximal medical therapy are given the
complement inhibitor C1-INH (Berinert) in an effort to protect the graft from ongoing
antibody mediated injury. A maximum of 5 patients will be enrolled.
Phase:
Phase 2
Details
Lead Sponsor:
Bonnie Lonze NYU Langone Health
Collaborator:
CSL Behring
Treatments:
Antibodies Complement C1 Inactivator Proteins Complement C1 Inhibitor Protein